1. Acetylshikonin exhibits weak cytotoxicity against human umbilical vein endothelial cells (HUVECs) with IC50 of over 20 microM, exhibits the antiangiogenic and antitumorigenic effects by suppressing proliferation and angiogenic factors.
2. Acetylshikonin inhibits the generation of NADPH oxidase complex in the activation of respiratory burst of PMNs, but does not directly inhibit the activity of NADPH oxidase already generated.
3. Certain shikonin derivatives(such as Acetyl shikonin) act as modulators of the Nur77-mediated apoptotic pathway and identify a new shikonin-based lead that targets Nur77 for apoptosis induction.
4. Acetylshikonin, shikonin, and alkannin have accelerative effect on the proliferation of granulation tissue in rats.
5. Acetylshikonin has inhibitory effect on the edematous response is due neither to the release of steroid hormones from the adrenal gland nor to the glucocorticoid activity, but probably partly to the suppression of mast cell degranulation and partly to protection of the vasculature from mediator challenge.
6. Acetylshikonin induces apoptosis of hepatitis B virus X protein-expressing human hepatocellular carcinoma cells via endoplasmic reticulum stress.
1. Acetylshikonin (ASK), a derivate of shikonin, can effectively inhibit tumor cells.
2. Acetylshikonin can be used to treat hepatocellular carcinoma cells expressing hepatitis B virus X protein (HBX) by inducing ER stress , an oncoprotein from hepatitis B virus.
3. Acetylshikonin exhibits the most potent antiapoptosis activity through the inhibition of the generation of reactive oxygen species as well as protection of the loss of mitochondria membrane potential.
4. Acetylshikonin inhibits the production of eicosanoid, is due to the attenuation of cytosolic phospholipase A(2) membrane recruitment via the decrease in [Ca(2+)](i) and to the blockade of cyclooxygenase and 5-lipoxygenase activity.
1. Aconine can inhibit RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
2. Aconine has GW26-e4470 effect on the expression of Sirt-1 and eNOS system in EAhy926 cell injured by Homocysteine.
3. Aconine can attenuate hepatic fat degeneration of rats with fatty liver induced by high-fat diet through decreasing TG,TC deposit in liver.
1. Aconitine, one of the major Aconitum alkaloids, is a highly toxic compound from the Aconitum species, in the causation of severe arrhythmias leading to death.
2. Aconitine appears to exert a long-lasting cholinergic action which may be involved in the genesis of aconitine-induced atrial fibrillation.
1. Acteoside is a lipase inhibitor, has anti-obesity properties.
2. Acteoside has neuroprotective activity, can promote nerve growth factor and tropomycin receptor kinase A expression.
3. Acteoside has anti-inflammatory activity, it significantly inhibits arachidonic acid release and prostaglandin E2 production induced by 0.5 microM melittin.
4. Acteoside has antioxidant activity, can protect the cells from X‑ray induced damage through enhancing the scavenging activity of ROS, decreasing the Bax/Bcl-2 ratio and downregulating the activity of procaspase-3, as well as modulating the mitogen‑activated protein kinase signaling pathways.
5. Acteoside exhibits anticancer, cytotoxic and antimetastatic activities, it is an antiestrogen in breast cancer cells and osteoblasts.
6. Acteoside has protective effects against the carbon tetrachloride-induced hepatotoxicity, the mechanisms possibly related to its ability to block the P450-mediated carbon tetrachloride bioactivation and free radical scavenging effects.
7. Acteoside inhibits human promyelocytic HL-60 leukemia cell proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation into monocyte.
8. Acteoside and its analogs have antioxidant and antihypertensive activities, it is a new antihypertensive drug.
9. Acteoside has analgesic activity, it as the Analgesic Principle of Cedron (Lippia hriphylla), a Peruvian Medicinal Plant.
1. Adenanthin has bacteriostatic activity.
2. Adenanthin has antiinflammatory activity.
3. Adenanthin has antitumour activity .
4. Adenanthin is a novel NF-κB and nucleophilic cysteines inhibitor.
5. Adenanthin has antileukemic activity through targeting peroxiredoxin I/II.
6. Adenanthin can serve as the development of Prx I– and Prx II–targeted therapeutic agents.
1. Adenine is a nucleic acid composition.
2. Adenine can increase the inhibitory activity of human interferon against encephalomyocarditis virus.
3. Adenine, an AMP-activated protein kinase (AMPK) activator, can accelerate the diabetic wound healing by PPAR delta and angiogenic regulation.
4. Adenine can act as an efficient radiation-protecting agent at low concentration (2 micromol) and also inhibit cytostatic properties with regard to cancer cells at higher concentration.
1. Adenosine induces SphK1 activity in human and mouse sickle and normal erythrocytes in vitro.
2. Adenosine can activate the neuroimmune system, alter neuronal function and neurotransmission,and contribute to symptoms of sickness and psychopathologies, .
3. Adenosine activates mast cells have been long implicated in allergic asthma and studies in rodent mast cells have assigned the A3 Adenosine receptor (A3R) a primary role in mediating Adenosine responses.
1. Adonifoline is a hepatotoxic pyrrolizidine alkaloid.